- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Addition of Toripalimab to Induction Improves PFS in Nonresectable NSCLC
June 2nd 2025, 2:29pm
Adding induction toripalimab to chemotherapy followed by definitive chemoradiotherapy and consolidation therapy reduced risk for disease progression by 74%.
Rusfertide Shines as New Treatment Option in Polycythemia Vera
June 2nd 2025, 1:50pm
In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.
Belantamab Mafodotin Triplet Improves PFS, Responses in R/R Myeloma With High-Risk Cytogenetics
June 2nd 2025, 12:55am
Belantamab mafodotin plus Pd improved PFS and response rates in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.
Dr Kuykendall on Clinical Benefit With Rusfertide in Phlebotomy-Dependent Polycythemia Vera
June 2nd 2025, 12:32am
Andrew Kuykendall, MD, discusses responses with rusfertide for patients with phlebotomy-dependent polycythemia vera.
Long-Term Data Demonstrate Sustained DFS Benefit With Adjuvant Pembrolizumab in ccRCC
June 1st 2025, 11:50pm
Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.
Dr Char on the Association Between the Empirical Dietary Inflammatory Pattern and Survival Outcomes in Stage III Colon Cancer
June 1st 2025, 11:40pm
Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.
Talquetamab Is Safe and Effective in R/R Multiple Myeloma
June 1st 2025, 10:49pm
Talquetamab led to durable responses and promising survival outcomes in patients with relapsed/refractory multiple myeloma.
Nivolumab/Ipilimumab Maintains Prolonged Survival and Generates Durable Responses in Advanced RCC
June 1st 2025, 10:20pm
First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.
Mitomycin/BCG Combo Could Alleviate BCG Shortage Concerns for NMIBC
June 1st 2025, 9:16pm
BCG plus mitomycin may represent good alternative to BCG alone in NMIBC.
Elraglusib Plus Chemotherapy Extends OS in Untreated Metastatic Pancreatic Ductal Adenocarcinoma
June 1st 2025, 8:50pm
Elraglusib plus gemcitabine/nab-paclitaxel displayed an OS benefit vs chemotherapy alone in untreated metastatic pancreatic ductal adenocarcinoma.
Sacituzumab Govitecan Plus Pembrolizumab Displays Activity in Early-Stage TNBC
June 1st 2025, 8:04pm
Sacituzumab govitecan in combination with pembrolizumab led to pathologic complete responses in early-stage triple-negative breast cancer.
Ribociclib Benefit Is Sustained in HR+ Early Breast Cancer Regardless of Age, Menopausal Status
June 1st 2025, 8:03pm
Ribociclib plus a nonsteroidal aromatase inhibitor improved iDFS, DDFS, RFS, and DRFS in HR+/HER2– early breast cancer.
Sacituzumab Tirumotecan Yields Superior Clinical Activity in EFGR+ NSCLC
June 1st 2025, 7:57pm
Sacituzumab tirumotecan showed statistically significant improvements in responses and survival vs docetaxel alone in advanced EGFR-mutant NSCLC.
Patritumab Deruxtecan Does Not Improve Overall Survival in EGFR-Mutated NSCLC
June 1st 2025, 7:55pm
Patritumab deruxtecan did not improve OS vs platinum-based chemotherapy in patients with EGFR mutation–positive locally advanced or metastatic NSCLC.
First-Line Nivolumab Plus Ipilimumab Does Not Boost OS in Cisplatin-Ineligible Unresectable Urothelial Carcinoma
June 1st 2025, 7:47pm
Nivolumab plus ipilimumab failed to improve overall survival in cisplatin-ineligible, unresectable urothelial carcinoma.
Savolitinib Plus Osimertinib Hits PFS End Point in EGFR-Mutated, MET-Amplified NSCLC After Disease Progression With an EGFR TKI
June 1st 2025, 7:35pm
Savolitinib plus osimertinib was safe and effective in patients with EGFR-mutated, MET-amplified advanced NSCLC after disease progression on an EGFR TKI.
Glofitamab/GemOx Enhances OS and PFS vs Rituximab in R/R DLBCL
June 1st 2025, 7:31pm
Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.
Cilta-Cel Boosts Survival Vs SOC Across Key Subgroups of R/R Multiple Myeloma
June 1st 2025, 7:16pm
CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.
Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC
June 1st 2025, 6:33pm
Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.
Nivolumab Plus Relatlimab Penetrates Blood-Brain Barrier in PD-(L)1-Refractory Melanoma With Brain Metastases
June 1st 2025, 5:00pm
Nivolumab plus relatlimab generated favorable intracranial responses in patients with advanced PD-(L)1-refractory melanoma with brain metastases.